Corpus Intelligence IC Memo — FRYE REGIONAL MEDICAL CENTER 2026-04-26 03:44 UTC
IC Memo — FRYE REGIONAL MEDICAL CENTER
Investment Committee Memorandum | NC | 226 beds | Grade C | EBITDA uplift $19.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

FRYE REGIONAL MEDICAL CENTER

CCN 340116 | CATAWBA, NC | 226 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

FRYE REGIONAL MEDICAL CENTER is a 226-bed suburban community hospital in CATAWBA, NC with $260.9M in net patient revenue and a -5.2% operating margin. The hospital serves a payer mix of 31.0% Medicare, 5.2% Medicaid, and 63.7% commercial.

Thesis: Undervalued. Our ML models identify $19.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -5.2% to 2.1% (+736bps).

Net Revenue HCRIS$260.9M
Current EBITDA COMPUTED$-13.7M
Operating Margin COMPUTED-5.2%
Occupancy HCRIS42.1%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS16.7%
Distress Probability ML49.4%

2. Market Context & Competitive Position

129
NC Hospitals
-2.0%
State Median Margin
41
Comparable Hospitals

NC has 129 Medicare-certified hospitals with a median operating margin of -2.0%. The target's margin of -5.2% places it below the state median. Among 41 size-comparable peers (113-452 beds), the median margin is 1.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (113-452), prioritizing same-state peers. 41 hospitals in the comp set.

HospitalStateBedsRevenueMargin
FRYE REGIONAL MEDICAL CENTER (Target)NC226$260.9M-5.2%
FIRSTHEALTH MOORE REGIONAL HOSNC412$813.8M8.8%
ATRIUM HEALTH CABARRUSNC447$758.9M13.9%
DUKE RALEIGH HOSPITALNC186$683.0M3.7%
GASTON MEMORIAL HOSPITALNC424$641.8M7.0%
ATRIUM HEALTH PINEVILLENC365$575.1M25.8%
CATAWBA VALLEY MEDICAL CENTERNC200$451.9M5.9%
DUKE REGIONAL HOSPITALNC301$421.0M-19.8%
HIGH POINT MEDICAL CENTERNC288$406.1M0.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $19.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.5M+210bp18mo
Cost to Collect4.5%2.5%$5.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$5.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.2M+122bp9mo
Clean Claim Rate88.0%96.0%$167K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.5M
Cost to Collect
$5.2M
Denial Rate Reduction
$5.2M
A/R Days Reduction
$3.2M
Clean Claim Rate
$167K
Total EBITDA Uplift$19.2M
Current EBITDA$-13.7M
+ RCM Uplift+$19.2M
Pro Forma EBITDA$5.5M
Current Margin-5.2%
Pro Forma Margin2.1%
WC Released (1x)$10.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-21.1M$101.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-21.1M$105.1M0.00x-100.0%
Bull Case9.0x11.0x$-18.9M$161.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-18.9M$170.7M0.00x-100.0%
Bear Case11.0x10.0x$-23.2M$12.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-23.2M$6.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 41 hospitals with 113-452 beds
  • Same-state prioritization (n=42)
  • Comp margins: P25=-6.2% / P50=1.0% / P75=8.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.